Shire/Avexa Expand Agreement On HIV Candidate Apricitabine
This article was originally published in The Pink Sheet Daily
Executive Summary
Acquisition of North American marketing rights to the novel nucleoside reverse transcriptase inhibitor gives Australian biotech Avexa worldwide commercialization rights.
You may also be interested in...
Gilead Raises HIV Franchise Prices
GSK also initiates price increase for its HIV drugs.
Bristol Eyes HIV Portfolio Expansion
Agreement with Medivir and in-house development of two inhibitors could add to Bristol’s HIV stable.
Roche To Stop Selling Early HIV Drug HIVID
The company will continue to supply zalcitabine, one of the first nucleoside reverse transcriptase inhibitors, through the end of the year.